Shares of Teladoc Health (NASDAQ:TDOC) fell in after-hours trading after the company reported earnings for its fourth quarter of Fiscal Year 2022. Earnings per share came in at a loss of $0.23, which beat analysts’ consensus estimate of a loss of $0.25 per share. Sales increased by 15.1% year-over-year, with revenue hitting $637.7 million. This beat analysts’ expectations of $633.37 million.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Teladoc Health saw revenue from access fees climb, ultimately hitting $553.7 million. That was up 16%, and other revenue sources saw similar gains. Other revenue was up to $84 million, a 10% increase. Teladoc’s percentage of revenue from the U.S. market, meanwhile, was up 15%, ultimately hitting $554.4 million. In addition, its international share reached $83.3 million, a 17% increase.
Looking forward, management now expects revenue for Q1 2023 to be in the range of $610 million to $625 million. EPS is expected to be in the range of a loss of $0.55 – $0.45. For reference, analysts were expecting $648.72 million in revenue and a loss of $0.43 in EPS.
Overall, Wall Street has a consensus price target of $32.18 on Teladoc with three Buys and nine Holds assigned, as indicated by the graphic above.
